March 6 (Reuters) - (This March 6 story has been refiled to say that Daiichi Sankyo is a co-developer of Enhertu)The ongoing DESTINY-PanTumor02 Phase II trial is assessing the efficacy and safety of Enhertu in patients with locally advanced or metastatic previously treated solid tumours that are not eligible for curative therapy, including cervical, ovarian, pancreatic, and rare cancersMarch 6 (Reuters) - (This March 6 story has been refiled to say that Daiichi Sankyo is a co-developer of Enhertu)The ongoing DESTINY-PanTumor02 Phase II trial is assessing the efficacy and safety of Enhertu in patients with locally advanced or metastatic previously treated solid tumours that are not eligible for curative therapy, including cervical, ovarian, pancreatic, and rare cancers